ProLung, which is developing a test that predicts early-stage risk of lung cancer, filed on Friday with the SEC to raise up to $8 million in an initial public offering.
The Salt Lake City, UT-based company was founded in 2004. It plans to list on the Nasdaq under the symbol LUNG. Maxim Group LLC is the sole bookrunner on the deal. No pricing terms were disclosed.
